MCID: END047
MIFTS: 50

Endophthalmitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Endophthalmitis

MalaCards integrated aliases for Endophthalmitis:

Name: Endophthalmitis 12 59 55 44 15 72

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 59  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:4692
MeSH 44 D009877
NCIt 50 C34586
SNOMED-CT 68 1847009 82255004
ICD10 33 H45.1
MESH via Orphanet 45 D009877
ICD10 via Orphanet 34 H44.0 H44.1
UMLS via Orphanet 73 C0014236
Orphanet 59 ORPHA199323
UMLS 72 C0014236

Summaries for Endophthalmitis

Disease Ontology : 12 A globe disease that is characterized by inflammation of the inside of the eye.

MalaCards based summary : Endophthalmitis is related to acute endophthalmitis and purulent endophthalmitis, and has symptoms including redness or discharge of eye An important gene associated with Endophthalmitis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are Development VEGF signaling via VEGFR2 - generic cascades and Fluid shear stress and atherosclerosis. The drugs Cefazolin and Clindamycin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and liver, and related phenotypes are hematopoietic system and immune system

Wikipedia : 75 Endophthalmitis is an inflammation of the interior of the eye. It is a possible complication of all... more...

Related Diseases for Endophthalmitis

Diseases in the Endophthalmitis family:

Chronic Endophthalmitis Acute Endophthalmitis

Diseases related to Endophthalmitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 524)
# Related Disease Score Top Affiliating Genes
1 acute endophthalmitis 34.4 VEGFA PRF1
2 purulent endophthalmitis 33.2 VEGFA PRF1 MRAP
3 corneal abscess 30.9 PLG DEFB1
4 diabetic macular edema 30.6 VEGFA ICAM1
5 vitreous detachment 30.5 VEGFA PLG
6 macular retinal edema 30.2 VEGFA MRAP ICAM1
7 hydrocele 30.0 VEGFA ICAM1
8 retinal vascular disease 30.0 VEGFA PLG ICAM1
9 proteasome-associated autoinflammatory syndrome 1 29.9 TLR2 SELE ICAM1
10 rosacea 29.8 VEGFA TLR2
11 opportunistic mycosis 29.3 TLR2 CARD9
12 neurofibromatosis, type ii 29.0 TLR2 DEFB1
13 chronic endophthalmitis 12.6
14 phacoanaphylactic uveitis 11.9
15 cataract 11.1
16 panuveitis 10.9
17 sympathetic ophthalmia 10.8
18 retinal detachment 10.8
19 hypopyon 10.8
20 uveitis 10.8
21 keratitis, hereditary 10.7
22 pars planitis 10.6
23 endocarditis 10.6
24 infectious panuveitis 10.6
25 anterior uveitis 10.6
26 yemenite deaf-blind hypopigmentation syndrome 10.5
27 heterophyiasis 10.5 SELE ICAM1
28 lymphocytic vasculitis 10.5 SELE ICAM1
29 intraocular pressure quantitative trait locus 10.5
30 mooren's ulcer 10.5 SELE ICAM1
31 meningitis 10.5
32 hymenolepiasis 10.5 SELE ICAM1
33 subendocardial myocardial infarction 10.5 SELE ICAM1
34 plummer's disease 10.5 SELE ICAM1
35 macrophage activation syndrome 10.5 PRF1 HMGB1
36 blind hypotensive eye 10.5
37 actinic prurigo 10.5 SELE ICAM1
38 macular degeneration, age-related, 1 10.5
39 rheumatoid vasculitis 10.5 SELE ICAM1
40 panophthalmitis 10.5
41 candidiasis 10.4
42 chorioretinitis 10.4
43 hypersensitivity reaction type iii disease 10.4 SELE ICAM1
44 neuroretinitis 10.4
45 retinitis 10.4
46 leukocyte adhesion deficiency, type i 10.4 SELE ICAM1
47 corneal ulcer 10.4
48 acute cystitis 10.4
49 osteonecrosis of the jaw 10.4 VEGFA DEFB1
50 localized scleroderma 10.4 SELE DEFB1

Graphical network of the top 20 diseases related to Endophthalmitis:



Diseases related to Endophthalmitis

Symptoms & Phenotypes for Endophthalmitis

UMLS symptoms related to Endophthalmitis:


redness or discharge of eye

MGI Mouse Phenotypes related to Endophthalmitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 CARD9 GON4L ICAM1 PLG PRF1 SELE
2 immune system MP:0005387 9.76 CARD9 GON4L ICAM1 PLG PRF1 SELE
3 integument MP:0010771 9.5 ASPRV1 ICAM1 PLG PRF1 SELE TLR2
4 neoplasm MP:0002006 9.1 GON4L ICAM1 PLG PRF1 TLR2 VEGFA

Drugs & Therapeutics for Endophthalmitis

DrugBank drugs 16 :

(show all 14)
# Drug Name Indication DrugBank ID
1 Amikacin The amikacin sulfate injection is indicated in the short-term treatment of serious bacterial infections due to susceptible strains of gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, as well as Acinetobacter (Mima-Herellea) species.[F1954] Clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery).[F1954] Clinical studies have shown amikacin also to be effective in serious, complicated, and recurrent urinary tract infections due to the above organisms. Aminoglycosides, including amikacin, are not indicated in uncomplicated first-time episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxic.[F1954] In September 2018, a new indication with a new dosage route was approved for this drug. Amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).[L4673] This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6 of treatment. Clinical benefit has not yet been established.[Label] **Important notes regarding Staphylococcus and Sensitivity testing:** Staphylococcus aureus, including methicillin-resistant strains, is the principal Gram-positive organism sensitive to amikacin. The use of amikacin in the treatment of staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibiotics.[F1949] Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be used as initial therapy in suspected gram-negative infections and therapy may be initiated before obtaining the results of susceptibility testing.[Label,F1949,F1954] DB00479
2 Atropine For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides. DB00572
3 Betamethasone DB00443
4 Bromfenac For the treatment of postoperative inflammation in patients who have undergone cataract extraction. DB00963
5 Diclofenac Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers. DB00586
6 Difluprednate For the treatment of inflammation and pain associated with ocular surgery. DB06781
7 Fluorometholone For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. DB00324
8 Loteprednol DB00873
9 Loteprednol etabonate A number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label]. DB14596
10 Polymyxin B Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of <i>Pseudomonas aeruginosa</i>[FDA Label]. DB00781
11 Prednisolone For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders. DB00860
12 Prednisone For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis. DB00635
13 Rimexolone For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis. DB00896
14 Triamcinolone For the treatment of perennial and seasonal allergic rhinitis. DB00620

Drugs for Endophthalmitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefazolin Approved Phase 4 25953-19-9 656510 33255
2
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
3
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
4
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
5
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Polyestradiol phosphate Approved Phase 4 28014-46-2
8
Bevacizumab Approved, Investigational Phase 4 216974-75-3
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Vancomycin Approved Phase 4 1404-90-6 441141 14969
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
14
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
15
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
16
Ranibizumab Approved Phase 4 347396-82-1 459903
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Bromfenac Approved Phase 4 91714-94-2 60726
22
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
23
Povidone Approved Phase 4 9003-39-8
24
Iodine Approved, Investigational Phase 4 7553-56-2 807
25
Povidone-iodine Approved Phase 4 25655-41-8
26
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
27
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
28 Cephalosporins Phase 4
29 Clindamycin phosphate Phase 4
30 Gentamicins Phase 4
31 Clindamycin palmitate Phase 4
32 Contraceptives, Oral Phase 4
33 Contraceptive Agents Phase 4
34 Contraceptives, Oral, Combined Phase 4
35 Norgestimate, ethinyl estradiol drug combination Phase 4
36 Estradiol 3-benzoate Phase 4
37 Estradiol 17 beta-cypionate Phase 4
38 Renal Agents Phase 4
39 Anti-Infective Agents, Urinary Phase 4
40 Triamcinolone hexacetonide Phase 4
41 Immunologic Factors Phase 4
42 triamcinolone acetonide Phase 4
43 Triamcinolone diacetate Phase 4
44 Immunosuppressive Agents Phase 4
45 HIV Protease Inhibitors Phase 4
46
protease inhibitors Phase 4
47 Antineoplastic Agents, Immunological Phase 4
48 Topoisomerase Inhibitors Phase 4
49 Mitogens Phase 4
50 Endothelial Growth Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery Unknown status NCT02324166 Phase 4 Cefazolin;Lidocaine
2 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
3 Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis Completed NCT00398658 Phase 4 gentamycin and clindamycin
4 Comparative Efficacy of Two Different Regimens of Povidone-iodine 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora Completed NCT01739920 Phase 4
5 Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children Completed NCT00461656 Phase 4 Preoperative conjunctival irrigation with 5% or 1.25% PI
6 Phase 4 Study on Effectiveness of Topical 0.5% Levofloxacin on Reduction of Preoperative Conjunctival Flora in Patients Scheduled for Intraocular Surgery Completed NCT00491049 Phase 4 0.5% levofloxacin eye drops
7 To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection Completed NCT00690313 Phase 4 Vigamox
8 A Two Different Chemoprophylaxis Approaches After Phacoemulsification Surgery in One Thousand Patients in Iraq :a Clinical Trial Completed NCT03634852 Phase 4 Moxifloxacin hydrochloride 0.5% eye drops;Dexamethasone 0.1% eye drops;Intracameral Moxifloxacin 0.1%;Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml
9 Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery Completed NCT02819908 Phase 4 Imprimis Dropless;Imprimis Less Drops
10 Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
11 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
12 Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen Completed NCT02515045 Phase 4 TriMoxiVanc;Moxifloxacin HCl 0.5%;Ilevro;Prednisolone acetate 1%
13 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
14 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
15 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
16 A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study) Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
17 Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Recruiting NCT03363295 Phase 4 Moxifloxacin Injection
18 Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen Recruiting NCT03578276 Phase 4 Pred-Gati-Brom;Prednisolone acetate 1% ophthalmic suspension;Gatifloxacin Ophthalmic;Bromfenac 0.075% Oph Solution
19 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
20 Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) Not yet recruiting NCT04018482 Phase 4
21 Randomized, Double Blind, Controlled Study With Verteporfin Photodynamic Therapy And Intravitreal Triamcinolone(IVTA) Vs Triple Therapy With Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone And Intravitreal Ranibizumab In Patients With Subfoveal Choroidal Neovascularization(CNV) Secondary To Age-Related Macular Degeneration(AMD) Unknown status NCT00930189 Phase 2, Phase 3 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone
22 Efficacy and Safety of Intravitreal Triamcinolone as Treatment of the Diffuse Diabetic Macular Edema Unknown status NCT00309192 Phase 3 Triamcinolone Acetonide 4 mg intravitreal injection
23 A Randomized, Prospective, Double Masked Clinical Trial of Life 4°C Versus Optisol GS Corneal Storage Media Unknown status NCT01657500 Phase 3
24 Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis. Completed NCT01768078 Phase 3
25 Endophthalmitis Vitrectomy Study (EVS) Completed NCT00000130 Phase 3 Intravitreal Antibiotics
26 Retaane® in Age-Related Macular Degeneration Completed NCT00569569 Phase 2, Phase 3 juxtascleral depot injection of Retaane
27 Clinical Study for Evaluating the Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration. Completed NCT03668054 Phase 3 Bevacizumab (Lumiere®)
28 Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA) Completed NCT00997191 Phase 3 Intravitreal triamcinolone;Intravitreal bevacizumab
29 Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration Completed NCT00531024 Phase 2, Phase 3 Bevacizumab;Sodium Chloride
30 The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Completed NCT00106132 Phase 3 Triamcinolone Acetonide
31 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
32 Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery Not yet recruiting NCT03244072 Phase 2, Phase 3 Moxifloxacin;Placebo
33 Intracameral Antibiotic Safety Study Not yet recruiting NCT02590523 Phase 3 Vancomycin;Moxifloxacin;Placebo
34 Use of Intracameral Moxifloxacin for the Prevention of Acute Endophthalmitis Following Cataract Surgery: a Controlled and Randomized Clinical Trial Terminated NCT02770729 Phase 3 Moxifloxacin;No injection of moxifloxacin
35 Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma Terminated NCT00901108 Phase 3
36 The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy Unknown status NCT00849537 Phase 1, Phase 2 Triamcinolone
37 Combined Posterior Sub-Tenon Injection of Triamcinolone Acetonide and Laser Photocoagulation for the Treatment of Clinically Significant Macular Edema Unknown status NCT00229918 Phase 2 triamcinolone acetonide
38 Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)? Unknown status NCT02405741 Phase 2
39 Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Completed NCT02595359 Phase 2 Moxifloxacin
40 Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration Completed NCT00805233 Phase 2 combination ranibizumab + bromfenac;ranibizumab injection alone
41 Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration Completed NCT00527475 Phase 2 ranibizumab;verteporfin
42 Comparative Study of the Efficacy and Safety of Ologen Collagen Implant Versus Cohesive Viscoelastic in Trabeculectomy Performed for Steroid Induced Glaucoma Completed NCT01912638 Phase 1, Phase 2 Provisc
43 An Open Label, Multicenter, Randomized, Uncontrolled Study Assessing the Safety and Efficacy of KH902 in Patients With Choroidal Neovascularization Due to Neovascular Age-related Macular Degeneration(HOPE Study) Completed NCT01242254 Phase 1, Phase 2
44 Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study Recruiting NCT02486484 Phase 2 ziv-aflibercept
45 Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery Terminated NCT00431028 Phase 1, Phase 2
46 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
47 The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study Unknown status NCT00855608 Phase 1 adalimumab
48 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
49 Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Completed NCT02294656 Phase 1 Ranibizumab,;Triamcinolone acetonide
50 A Randomized, Prospective Study of Sustained-Release Fluocinolone Acetonide Implant for Choroidal Neovascularization Associated With Age-Related Macular Degeneration Completed NCT00008515 Phase 1 Fluocinolone

Search NIH Clinical Center for Endophthalmitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Amikacin
Atropine
Betamethasone
Bromfenac
Diclofenac
Difluprednate
Fluorometholone
Loteprednol
Loteprednol etabonate
Polymyxin B
Prednisolone
Prednisone
Rimexolone
Triamcinolone

Cochrane evidence based reviews: endophthalmitis

Genetic Tests for Endophthalmitis

Anatomical Context for Endophthalmitis

MalaCards organs/tissues related to Endophthalmitis:

41
Eye, Endothelial, Liver, Retina, Testes, Lung, Colon

Publications for Endophthalmitis

Articles related to Endophthalmitis:

(show top 50) (show all 7670)
# Title Authors PMID Year
1
Molecular epidemiology of Staphylococcus aureus and Enterococcus faecalis in endophthalmitis. 9 38
9423880 1998
2
Virulence of enterococci. 9 38
7834601 1994
3
Criteria for intravitreal antibiotics during surgical removal of intraocular foreign bodies. 9 38
1286707 1992
4
Posterior Segment Complications and Impact on Long-Term Visual Outcomes in Eyes With a Type 1 Boston Keratoprosthesis. 38
31232746 2019
5
Complete Genome Sequence of Massilia oculi sp. nov. CCUG 43427T (=DSM 26321T), the Type Strain of M. oculi, and Comparison with Genome Sequences of Other Massilia Strains. 38
30443686 2019
6
INADVERTENT INTRAOCULAR SURGERY IN CHILDREN WITH UNSUSPECTED RETINOBLASTOMA: A Study of 14 Cases. 38
29863537 2019
7
Pseudozyma aphidis endophthalmitis post-cataract operation: Case discussion and management. 38
31198884 2019
8
Injectable Schiff base polysaccharide hydrogels for intraocular drug loading and release. 38
30950154 2019
9
Commentary: Clinical presentations and comparative outcomes of primary versus deferred intraocular lens explantation in delayed-onset endophthalmitis. 38
31436217 2019
10
Paediatric endophthalmitis: a UK retrospective study. 38
31406355 2019
11
Listeria endophthalmitis in a patient receiving immunomodulatory therapy. 38
31345463 2019
12
Traumatic Staphylococcus gallinarum endophthalmitis and detachment of a pallid retina. 38
31434672 2019
13
[Vitrectomy for endophthalmitis : Incubation time and prognosis following intravitreal injection vs. cataract surgery]. 38
30421147 2019
14
Endophthalmitis after intravitreal injections versus cataract surgery: a 15-year cohort. 38
31414274 2019
15
The Prevalence of Bacteria, Fungi, Viruses, and Acanthamoeba From 3,004 Cases of Keratitis, Endophthalmitis, and Conjunctivitis. 38
31373904 2019
16
Posterior Segment Visualization in Eyes With Small-Aperture Intraocular Lens. 38
31393993 2019
17
Current Practice Preferences and Safety Protocols for Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. 38
31068264 2019
18
Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016. 38
31415382 2019
19
Indications and Outcomes for the Removal of Intraocular Lens Implants in a Retinal Surgery Practice. 38
31415697 2019
20
[Advance study of rhinocerebralmucormycosis]. 38
31422642 2019
21
Postoperative Cataract Endophthalmitis Masquerading as Hemorrhagic Occlusive Retinal Vasculitis (HORV): A Case Report. 38
31414916 2019
22
Successful Clinical Outcome of Vancomycin-induced Hemorrhagic Occlusive Retinal Vasculitis. 38
31418634 2019
23
Endogenous Bacterial Endophthalmitis: A Five-Year Retrospective Review at a Tertiary Care Academic Center. 38
31418616 2019
24
Bilateral endophthalmitis as the initial presentation of pneumococcal endocarditis. 38
30553620 2019
25
Infectious uveitis in immunodeficient HIV-negative patients: A retrospective study. 38
31435074 2019
26
The Impact of Primary Treatment on Post-Traumatic Endophthalmitis in Children with Open Globe Injuries: A Study in China. 38
31426389 2019
27
Ocular culture-proven endogenous endophthalmitis: a 5-year retrospective study of the microorganism spectrum at a tertiary referral center in Turkey. 38
30051217 2019
28
RE: Stem MS, et al: Predictors of Endophthalmitis after Intravitreal Injection: A multivariable analysis based on injection protocol and povidone iodine strength (Ophthalmol Retina. 2019;3:3-7). 38
31383399 2019
29
Prophylactic intracameral cefazolin and postoperative topical moxifloxacin after cataract surgery: endophthalmitis risk reduction and safety results in a 16-year study. 38
31392416 2019
30
Bilateral Endophthalmitis after Immediately Sequential Bilateral Cataract Surgery. 38
31153851 2019
31
CLOSTRIDIAL ENDOPHTHALMITIS: CLINICAL PRESENTATIONS, MANAGEMENT OUTCOMES, AND REVIEW OF LITERATURE. 38
31344009 2019
32
Bleb-associated endophthalmitis: Proportion, presentation, management and outcomes in Victoria, Australia. 38
30788894 2019
33
Pathogenic causes and outcomes of endophthalmitis after vitreoretinal surgeries in Finland from 2009 to 2018. 38
31352683 2019
34
Clinical presentations and comparative outcomes of primary versus deferred intraocular lens explantation in delayed-onset endophthalmitis. 38
31238420 2019
35
Bacteroides Spp. Blebitis, Keratitis, and Endophthalmitis Following Uncomplicated Trabeculectomy. 38
30855413 2019
36
Extraocular and Intraocular Infections Following Strabismus Surgery: A Review. 38
31322710 2019
37
Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study. 38
31277797 2019
38
Risk factors for orbital implant exposure after evisceration: A case control study of 93 patients. 38
31238431 2019
39
Interplay between IDO1 and iNOS in human retinal pigment epithelial cells. 38
31267172 2019
40
Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation. 38
30485637 2019
41
Results of cataract surgery in a third-level teaching hospital. More than just a simple number. 38
31337520 2019
42
Pyogenic Granuloma Formation Following Ahmed Valve Glaucoma Implant. 38
31368915 2019
43
Cyclophotocoagulation in the Control of Glaucoma in Patients With the Boston Keratoprosthesis Type 1. 38
31335536 2019
44
Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study. 38
31080168 2019
45
Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. 38
31081526 2019
46
Multifocal electroretinogram in eyes with intravitreal silicone oil and changes following silicone oil removal. 38
31327119 2019
47
Scleritis and endophthalmitis due to Streptococcus pyogenes infective endocarditis. 38
31351838 2019
48
Toxic anterior segment syndrome: A review. 38
30703402 2019
49
Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells. 38
31278356 2019
50
Outcome of phacoemulsification in 71 cats: A multicenter retrospective study (2006-2017). 38
31328856 2019

Variations for Endophthalmitis

Expression for Endophthalmitis

Search GEO for disease gene expression data for Endophthalmitis.

Pathways for Endophthalmitis

GO Terms for Endophthalmitis

Cellular components related to Endophthalmitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 VEGFA SELE PLG ICAM1 HMGB1 DEFB1
2 membrane raft GO:0045121 9.33 TLR2 SELE ICAM1
3 cell surface GO:0009986 9.02 VEGFA TLR2 PLG ICAM1 HMGB1

Biological processes related to Endophthalmitis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.81 TLR2 HMGB1 DEFB1 CARD9
2 response to hypoxia GO:0001666 9.65 VEGFA TLR2 ICAM1
3 response to lipopolysaccharide GO:0032496 9.61 TLR2 SELE ICAM1
4 ovarian follicle development GO:0001541 9.56 VEGFA ICAM1
5 toll-like receptor signaling pathway GO:0002224 9.55 TLR2 HMGB1
6 leukocyte cell-cell adhesion GO:0007159 9.52 SELE ICAM1
7 positive regulation of interleukin-12 production GO:0032735 9.46 TLR2 HMGB1
8 defense response to Gram-positive bacterium GO:0050830 9.43 TLR2 DEFB1 CARD9
9 positive regulation of interleukin-10 production GO:0032733 9.4 TLR2 HMGB1
10 positive regulation of innate immune response GO:0045089 9.37 HMGB1 CARD9
11 positive regulation of receptor internalization GO:0002092 9.32 VEGFA SELE
12 positive regulation of sprouting angiogenesis GO:1903672 9.24 VEGFA
13 positive regulation of interferon-beta production GO:0032728 9.19 TLR2
14 positive regulation of interleukin-6 production GO:0032755 9.13 TLR2 HMGB1 CARD9
15 endothelial cell chemotaxis GO:0035767 8.85 VEGFA
16 positive regulation of tumor necrosis factor production GO:0032760 8.8 TLR2 HMGB1 CARD9

Molecular functions related to Endophthalmitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.16 VEGFA HMGB1
2 identical protein binding GO:0042802 9.02 VEGFA TLR2 PRF1 MRAP DEFB1
3 lipopolysaccharide binding GO:0001530 8.96 TLR2 HMGB1

Sources for Endophthalmitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....